Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital)

Contract Research Services (Outsourced Clinical Development)

Disease Overview

Contract research organizations (CROs) provide outsourced clinical development services — protocol design, site management, monitoring, biostatistics, regulatory submissions, and pharmacovigilance — to biotech and pharma sponsors. They are not therapeutic providers; they are infrastructure for the industry. CRO penetration grew through the 2010s as sponsors variabilized fixed R&D costs and accessed global trial networks.

Competitive Landscape

By 2013 the CRO industry had entered a rapid consolidation phase, with Sterne Agee analyst Greg Bolan noting 17 moderate-to-large pharma-services M&A deals over the prior four years at TTM EBITDA multiples of 10-14x. The Tier-1 global full-service competitive set was Quintiles (which IPO'd at $947M in May 2013 and set the public-market template), Covance, Parexel, ICON, PPD (also PE-owned by Carlyle/Hellman & Friedman), and inVentiv. PRA International ranked just below this top tier with 5,300+ employees in 80 countries and a 2,000-trial track record across the prior 12 years. KKR's $1.3B take-private from Genstar Capital — a 1.6x return on Genstar's $797M 2007 entry — was financed with $950M in leveraged loans (Bloomberg) and immediately bolted on ReSearch Pharmaceutical Services (RPS) in September 2013, creating the #4 global CRO and adding RPS's 'embedded' clinical-development model to PRA's traditional outsourced platform. KKR exited via a $375M IPO in November 2014, validating the consolidation thesis and the IPO playbook Quintiles had just demonstrated. (Sources: fiercebiotech.com 2013-06-24; bloomberg.com 2013-08-15; businesswire.com 2013-09-24.)